{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T15:47:03Z","timestamp":1792424823590,"version":"4.5.0"},"reference-count":57,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,3,1]],"date-time":"2018-03-01T00:00:00Z","timestamp":1519862400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100004048","name":"Kashan University of Medical Sciences","doi-asserted-by":"publisher","award":["1200 $"],"award-info":[{"award-number":["1200 $"]}],"id":[{"id":"10.13039\/501100004048","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Progress in Neuro-Psychopharmacology and Biological Psychiatry"],"published-print":{"date-parts":[[2018,3]]},"DOI":"10.1016\/j.pnpbp.2017.11.001","type":"journal-article","created":{"date-parts":[[2017,11,7]],"date-time":"2017-11-07T09:03:09Z","timestamp":1510045389000},"page":"289-296","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":94,"special_numbering":"C","title":["Therapeutic effect of adjunctive N-acetyl cysteine (NAC) on symptoms of chronic schizophrenia: A double-blind, randomized clinical trial"],"prefix":"10.1016","volume":"82","author":[{"given":"Zahra","family":"Sepehrmanesh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9843-1295","authenticated-orcid":false,"given":"Mahsa","family":"Heidary","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Negar","family":"Akasheh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hossein","family":"Akbari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahshid","family":"Heidary","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.pnpbp.2017.11.001_bb0005","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1515\/CCLM.2000.201","article-title":"Erythrocyte superoxide dismutase and glutathione peroxidase activities, and malondialdehyde and reduced glutathione levels in schizophrenic patients","volume":"38","author":"Altuntas","year":"2000","journal-title":"Clin. Chem. Lab. Med."},{"key":"10.1016\/j.pnpbp.2017.11.001_bb0010","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1080\/14734220601142878","article-title":"N-Acetylcysteine and neurodegenerative diseases: basic and clinical pharmacology","volume":"6","author":"Arakawa","year":"2007","journal-title":"Cerebellum"},{"issue":"4","key":"10.1016\/j.pnpbp.2017.11.001_bb0015","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.coph.2007.04.005","article-title":"N-Acetylcysteine: a safe antidote for cysteine\/glutathione deficiency","volume":"7","author":"Atkuri","year":"2007","journal-title":"Curr. Opin. Pharmacol."},{"issue":"4","key":"10.1016\/j.pnpbp.2017.11.001_bb0020","first-page":"351","article-title":"Confirmatory factor analysis of positive and negative affect scale","volume":"9","author":"Bakhshipour Roudsari","year":"2005","journal-title":"J. Psychol."},{"key":"10.1016\/j.pnpbp.2017.11.001_bb0025","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/j.biopsych.2008.03.004","article-title":"N-Acetyl cysteine as a glutathione precursor for schizophrenia \u2013 a double-blind, randomized, placebo-controlled trial","volume":"64","author":"Berk","year":"2008","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.pnpbp.2017.11.001_bb0030","doi-asserted-by":"crossref","first-page":"909","DOI":"10.4088\/JCP.09m05741yel","article-title":"Qualitative methods in early-phase drug trials: broadening the scope of data and methods from an RCT of N-acetylcysteine in schizophrenia","volume":"72","author":"Berk","year":"2011","journal-title":"J. Clin. Psychiatry"},{"issue":"3","key":"10.1016\/j.pnpbp.2017.11.001_bb0035","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1016\/j.neubiorev.2010.10.008","article-title":"Oxidative stress in schizophrenia: an integrated approach","volume":"35","author":"Bitanihirwe","year":"2011","journal-title":"Neurosci. Biobehav. Rev."},{"key":"10.1016\/j.pnpbp.2017.11.001_bb0040","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1097\/CHI.0b013e3181ae09f3","article-title":"Trichotillomania across the life span","volume":"48","author":"Bloch","year":"2009","journal-title":"J. Am. Acad. Child Adolesc. Psychiatry"},{"issue":"2","key":"10.1016\/j.pnpbp.2017.11.001_bb0045","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1097\/YCO.0b013e328017f69f","article-title":"Pharmacogenetics of antipsychotics: useful for the clinician?","volume":"20","author":"Bondy","year":"2007","journal-title":"Curr. Opin. Psychiatry"},{"key":"10.1016\/j.pnpbp.2017.11.001_bb0050","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1080\/15622970903144004","article-title":"Beneficial effects of N-acetylcysteine in treatment resistant schizophrenia","volume":"10","author":"Bulut","year":"2009","journal-title":"World J. Biol. Psychiatry"},{"key":"10.1016\/j.pnpbp.2017.11.001_bb0055","article-title":"N-Acetyl-Cysteine in a double-blind randomized placebo-controlled trial: towards biomarker guided treatment in early psychosis","author":"Conus","year":"2017","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.pnpbp.2017.11.001_bb0060","doi-asserted-by":"crossref","first-page":"2386","DOI":"10.1001\/jama.1993.03500180078038","article-title":"Population-based norms for the Mini-Mental State Examination by age and educational level","volume":"269","author":"Crum","year":"1993","journal-title":"JAMA"},{"key":"10.1016\/j.pnpbp.2017.11.001_bb0065","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/j.burns.2011.09.011","article-title":"Effect of N-acetylcysteine treatment on oxidative stress and inflammation after severe burn","volume":"38","author":"Csontos","year":"2012","journal-title":"Burns"},{"issue":"2","key":"10.1016\/j.pnpbp.2017.11.001_bb0070","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1093\/schbul\/sbn097","article-title":"Systemic hypotheses for generalized cognitive deficits in schizophrenia: a new take on an old problem","volume":"35","author":"Dickinson","year":"2009","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.pnpbp.2017.11.001_bb0075","doi-asserted-by":"crossref","first-page":"3721","DOI":"10.1046\/j.1460-9568.2000.00229.x","article-title":"Schizophrenia: glutathione deficit in cerebro spinal fluid and prefrontal cortex in vivo","volume":"12","author":"Do","year":"2000","journal-title":"Eur. J. Neurosci."},{"key":"10.1016\/j.pnpbp.2017.11.001_bb0080","doi-asserted-by":"crossref","first-page":"1955","DOI":"10.1517\/14728220802517901","article-title":"N-acetylcysteine for antioxidant therapy: pharmacology and clinical utility","volume":"8","author":"Dodd","year":"2008","journal-title":"Expert. Opin. Biol. Ther."},{"key":"10.1016\/j.pnpbp.2017.11.001_bb0085","doi-asserted-by":"crossref","unstructured":"Farokhnia, M., Azarkolah, A., Adinehfar, F., Khodaie-Ardakani, M.R., 2013. N-Acetylcysteine as an adjunct to risperidone for treatment of negative symptom in patients with chronic schizophrenia: a randomized, double- blind, placebo-controlled study. Nov\u2013Dec. 36(6), 182\u2013192.","DOI":"10.1097\/WNF.0000000000000001"},{"key":"10.1016\/j.pnpbp.2017.11.001_bb0090","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1017\/S1461145710000805","article-title":"Decreased levels of glutathione, the major brain antioxidant, in post-mortem prefrontal cortex from patients with psychiatric disorders","volume":"8","author":"Gawryluk","year":"2011","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.pnpbp.2017.11.001_bb0095","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1002\/bmc.1171","article-title":"The effect of N-acetylcysteine on amphetamine-mediated dopamine release in rat brain striatal slices by ion-pair reversed-phase high performance liquid chromatography","volume":"23","author":"Gere-Paszti","year":"2009","journal-title":"Biomed. Chromatogr."},{"issue":"50","key":"10.1016\/j.pnpbp.2017.11.001_bb0100","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1192\/bjp.191.50.s64","article-title":"Adverse effects of antipsychotics as outcome measures","author":"Hamer","year":"2007","journal-title":"Br. J. Psychiatry Suppl."},{"issue":"2","key":"10.1016\/j.pnpbp.2017.11.001_bb0105","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1038\/nrn.2015.19","article-title":"Linking early-life NMDAR hypofunction and oxidative stress in schizophrenia pathogenesis","volume":"17","author":"Hardingham","year":"2016","journal-title":"Nat. Rev. Neurosci."},{"key":"10.1016\/j.pnpbp.2017.11.001_bb0110","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1192\/bjp.178.6.506","article-title":"Recovery from psychotic illness: a 15- and 25-year international follow-up study","volume":"178","author":"Harrison","year":"2001","journal-title":"Br. J. Psychiatry"},{"key":"10.1016\/j.pnpbp.2017.11.001_bb0115","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1016\/j.nbd.2011.12.031","article-title":"Amelioration of social isolation-triggered onset of early Alzheimer's disease-related cognitive deficit by N-acetylcysteine in a transgenic mouse model","volume":"45","author":"Hsiao","year":"2012","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.pnpbp.2017.11.001_bb0120","doi-asserted-by":"crossref","first-page":"2618","DOI":"10.1002\/jnr.22422","article-title":"Potential in vivo amelioration by N-acetyl-L-cysteine of oxidative stress in brain in human double mutant APP\/PS-1 knock-in mice: toward therapeutic modulation of mild cognitive impairment","volume":"88","author":"Huang","year":"2010","journal-title":"J. Neurosci. Res."},{"key":"10.1016\/j.pnpbp.2017.11.001_bb0125","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/S0920-9964(02)00314-6","article-title":"Cognitive predictors of medication adherence among middle-aged and older outpatients with schizophrenia","volume":"63","author":"Jeste","year":"2003","journal-title":"Schizophr. Res."},{"issue":"2","key":"10.1016\/j.pnpbp.2017.11.001_bb8120","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1093\/schbul\/13.2.261","article-title":"The positive and negative syndrome scale (PANSS) for schizophrenia","volume":"13","author":"Kay","year":"1987","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.pnpbp.2017.11.001_bb0130","doi-asserted-by":"crossref","first-page":"2033","DOI":"10.1038\/sj.npp.1301072","article-title":"Baseline neurocognitive deficits in the CATIE schizophrenia trail","volume":"31","author":"Keefe","year":"2006","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.pnpbp.2017.11.001_bb0135","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.expneurol.2011.10.025","article-title":"System x(c)(-) regulates microglia and macrophage glutamate excitotoxicity in vivo","volume":"23","author":"Kigerl","year":"2012","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.pnpbp.2017.11.001_bb0140","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.1038\/sj.npp.1301624","article-title":"Glutathione precursor, N-acetyl-cysteine, improves mismatch negativity in schizophrenia patients","volume":"33","author":"Lavoie","year":"2008","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.pnpbp.2017.11.001_bb0145","first-page":"102","article-title":"Should cognitive deficit be diagnostic criterion for schizophrenia?","volume":"29","author":"Lewis","year":"2004","journal-title":"J. Psychiatry Neurosci."},{"key":"10.1016\/j.pnpbp.2017.11.001_bb0150","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1124\/mol.109.059865","article-title":"Glutamatergic (N methyl-Daspartate receptor) hypofrontality in schizophrenia: too little juiceor a miswired brain?","volume":"77","author":"Marek","year":"2010","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.pnpbp.2017.11.001_bb0155","doi-asserted-by":"crossref","first-page":"195","DOI":"10.3233\/JAD-2007-12210","article-title":"Lipoic acid and N-acetyl cysteine decrease mitochondrial-related oxidative stress in Alzheimer disease patient fibroblasts","volume":"12","author":"Moreira","year":"2007","journal-title":"J. Alzheimers Dis."},{"key":"10.1016\/j.pnpbp.2017.11.001_bb0160","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1055\/s-0042-101557","article-title":"Duloxetine add-on to risperidone for treatment of negative symptoms in patients with stable schizophrenia: randomized double-blind placebo controlled study","volume":"49","author":"Nikbakhat","year":"2016","journal-title":"Pharmacopsychiatry"},{"key":"10.1016\/j.pnpbp.2017.11.001_bb0165","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1016\/j.pbb.2011.04.015","article-title":"Glutamatergic medications for the treatment of drug and behavioral addictions","volume":"100","author":"Olive","year":"2012","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/j.pnpbp.2017.11.001_bb0170","doi-asserted-by":"crossref","first-page":"2233","DOI":"10.1038\/npp.2011.109","article-title":"N-Acetyl cysteine treatment rescues cognitive deficits induced by mitochondrial dysfunction in G72\/G30 transgenic mice","volume":"36","author":"Otte","year":"2011","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.pnpbp.2017.11.001_bb0175","first-page":"157","article-title":"Oxidative stress asmarkers of positive symptoms in schizophrenia","volume":"9","author":"Pavlovic","year":"2002","journal-title":"Med. Biol."},{"key":"10.1016\/j.pnpbp.2017.11.001_bb0180","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1186\/1471-244X-11-124","article-title":"Decreased glutathione levels and impaired antioxidant enzyme activities in drug-naive first-episode schizophrenic patients","volume":"11","author":"Raffa","year":"2011","journal-title":"BMC Psychiatry"},{"key":"10.1016\/j.pnpbp.2017.11.001_bb0185","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1017\/S0033291716002932","article-title":"Cognitive effects of adjunctive N-acetyl cysteine in psychosis","volume":"47","author":"Rapado-Castro","year":"2017","journal-title":"Psychol. Med."},{"issue":"7","key":"10.1016\/j.pnpbp.2017.11.001_bb0190","doi-asserted-by":"crossref","first-page":"2047","DOI":"10.1089\/ars.2010.3571","article-title":"Antioxidant therapeutics for schizophrenia","volume":"15","author":"Reddy","year":"2011","journal-title":"Antioxid. Redox Signal."},{"key":"10.1016\/j.pnpbp.2017.11.001_bb0195","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1097\/JCP.0b013e31828b50a7","article-title":"Memantine add-on to risperidone for treatment of negative symptoms in patients with stable schizophrenia: randomized, double-blind, placebocontrolled study","volume":"33","author":"Rezaei","year":"2013","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.pnpbp.2017.11.001_bb0200","series-title":"Synopsis of Psychiatry","first-page":"471","author":"Sadock","year":"2007"},{"key":"10.1016\/j.pnpbp.2017.11.001_bb0205","series-title":"Kaplan & Sadock's comprehensive textbook of psychiatry","first-page":"1432","author":"Sadock","year":"2009"},{"key":"10.1016\/j.pnpbp.2017.11.001_bb0210","doi-asserted-by":"crossref","first-page":"557","DOI":"10.3389\/fpsyg.2017.00557","article-title":"The stroop color and word test","volume":"8","author":"Scarpina","year":"2017","journal-title":"Front. Psychol."},{"issue":"2","key":"10.1016\/j.pnpbp.2017.11.001_bb0215","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.mehy.2006.12.028","article-title":"Symptoms of schizophrenia: normal adaptations to inability","volume":"69","author":"Seeman","year":"2007","journal-title":"Med. Hypotheses"},{"key":"10.1016\/j.pnpbp.2017.11.001_bb0220","first-page":"408","article-title":"Validity of the Farsi version of mini-mental state examination","volume":"25","author":"Seyedian","year":"2008","journal-title":"J. Med. Counc. I.R.I."},{"key":"10.1016\/j.pnpbp.2017.11.001_bb0225","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.neubiorev.2017.04.013","article-title":"The effect of N-acetylcysteine (NAC) on human cognition\u2013a systematic review","volume":"78","author":"Skvarc","year":"2017","journal-title":"Neurosci. Biobehav. Rev."},{"issue":"7","key":"10.1016\/j.pnpbp.2017.11.001_bb0230","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1016\/j.neuroscience.2005.10.014","article-title":"Synaptic plasticity impairment and hypofunction of NMDA receptors induced by glutathione deficit: relevance to schizophrenia","volume":"13","author":"Steullet","year":"2006","journal-title":"Neuroscience"},{"key":"10.1016\/j.pnpbp.2017.11.001_bb0235","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/S0920-9964(01)00329-2","article-title":"The effect of melperone, an atypical antipsychotic drug, on cognitive function in schizophrenia","volume":"59","author":"Sumiyoshi","year":"2003","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.pnpbp.2017.11.001_bb0240","series-title":"Stroop Neuropsychological Screening Test","author":"Trenerry","year":"1989"},{"key":"10.1016\/j.pnpbp.2017.11.001_bb0245","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1111\/j.1442-9071.2009.02000.x","article-title":"Effect of N-acetylcysteine on the early expression of inflammatory markers in the retina and plasma of diabetic rats","volume":"37","author":"Tsai","year":"2009","journal-title":"Clin. Exp. Ophthalmol."},{"key":"10.1016\/j.pnpbp.2017.11.001_bb0250","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1007\/s00213-002-1250-8","article-title":"Cognitive enhancing effects of modafinil in healthy volunteers","volume":"165","author":"Turner","year":"2003","journal-title":"Psychopharmacology"},{"issue":"7","key":"10.1016\/j.pnpbp.2017.11.001_bb0255","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1002\/jcb.22196","article-title":"Reactive oxygen species-induced cell death of rat primary astrocytes through mitochondria-mediated mechanism","volume":"10","author":"Wang","year":"2009","journal-title":"J. Cell. Biochem."},{"key":"10.1016\/j.pnpbp.2017.11.001_bb0260","series-title":"Wechsler Adult Intelligence Scale F Revised","author":"Wechsler","year":"1981"},{"issue":"9","key":"10.1016\/j.pnpbp.2017.11.001_bb0265","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.4088\/JCP.v66n0906","article-title":"The economic burden of schizophrenia in the United States in 2002","volume":"66","author":"Wu","year":"2005","journal-title":"J. Clin. Psychiatry"},{"issue":"7","key":"10.1016\/j.pnpbp.2017.11.001_bb0270","doi-asserted-by":"crossref","first-page":"2011","DOI":"10.1089\/ars.2010.3603","article-title":"Antioxidants, redox signaling, and pathophysiology in schizophrenia: an integrative view","volume":"15","author":"Yao","year":"2011","journal-title":"Antioxid. Redox Signal."},{"key":"10.1016\/j.pnpbp.2017.11.001_bb0275","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1155\/2006\/248387","article-title":"Altered glutathione redox state in schizophrenia","volume":"22","author":"Yao","year":"2006","journal-title":"Dis. Markers"},{"key":"10.1016\/j.pnpbp.2017.11.001_bb0280","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1007\/s000180300001","article-title":"Molecular mechanisms of N-acetylcysteine actions","volume":"60","author":"Zafarullah","year":"2003","journal-title":"Cell. Mol. Life Sci."}],"container-title":["Progress in Neuro-Psychopharmacology and Biological Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0278584617307236?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0278584617307236?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,28]],"date-time":"2024-06-28T11:02:27Z","timestamp":1719572547000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0278584617307236"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,3]]},"references-count":57,"alternative-id":["S0278584617307236"],"URL":"https:\/\/doi.org\/10.1016\/j.pnpbp.2017.11.001","relation":{},"ISSN":["0278-5846"],"issn-type":[{"value":"0278-5846","type":"print"}],"subject":[],"published":{"date-parts":[[2018,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Therapeutic effect of adjunctive N-acetyl cysteine (NAC) on symptoms of chronic schizophrenia: A double-blind, randomized clinical trial","name":"articletitle","label":"Article Title"},{"value":"Progress in Neuro-Psychopharmacology and Biological Psychiatry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pnpbp.2017.11.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}